Merck Discontinues Key Antibiotic Amid Rising Concerns Over Superbugs

MIAMI — September 29, 2026

In a significant development for public health, Merck & Co. announced on September 29, 2026, that it will discontinue the production and sale of its antibiotic, Invanz (ertapenem), in the United States. This decision comes amid growing concerns about the rising threat of multidrug-resistant infections, commonly referred to as superbugs, which pose a serious challenge to healthcare systems globally.

Invanz, which has been a critical treatment option for various infections, including those caused by resistant bacteria, is now set to be pulled from the market, raising alarms among healthcare professionals and public health officials. The announcement was made public through a statement released by Merck, detailing the company’s rationale for the discontinuation.

The decision to withdraw Invanz is reportedly driven by a combination of factors, including declining sales and the increasing prevalence of antibiotic resistance. According to Merck, the company has faced challenges in maintaining the drug’s market viability, which has been compounded by the emergence of alternative therapies and the ongoing scrutiny of antibiotic use in clinical settings.

As of 2026, the Centers for Disease Control and Prevention (CDC) has identified antibiotic resistance as one of the most pressing public health threats, estimating that at least 2.8 million infections and 35,000 deaths occur each year in the United States due to antibiotic-resistant bacteria. The withdrawal of Invanz is likely to exacerbate this crisis, as healthcare providers may find themselves with fewer effective treatment options.

This development is particularly concerning given the backdrop of the COVID-19 pandemic, which has already strained healthcare resources and highlighted the vulnerabilities within the healthcare system. The timing of Merck’s announcement has drawn significant attention, as it coincides with ongoing discussions about the need for new antibiotics and the importance of stewardship in antibiotic prescribing practices.

Merck’s decision is not only a blow to healthcare providers but also raises questions about the pharmaceutical industry’s commitment to developing new antibiotics. The company has not indicated whether it plans to invest in alternative treatments or research to address the growing threat of superbugs.

Looking ahead, the discontinuation of Invanz may prompt increased advocacy for the development of new antibiotics and alternative therapies. Public health officials and healthcare providers will likely call for renewed efforts to combat antibiotic resistance, including enhanced surveillance, research funding, and educational initiatives aimed at promoting responsible antibiotic use.

In summary, Merck’s decision to withdraw Invanz from the U.S. market underscores the urgent need for innovative solutions to address the escalating crisis of antibiotic resistance, a challenge that affects not only the United States but also global health security.

Source: STAT